Skip to Content
Merck
All Photos(1)

Documents

PHR1271

Supelco

Levodopa

Pharmaceutical Secondary Standard; Certified Reference Material

Synonym(s):

3,4-Dihydroxy-L-phenylalanine, 3-(3,4-Dihydroxyphenyl)-L-alanine, L-3-Hydroxytyrosine, L-DOPA, Levodopa

Sign Into View Organizational & Contract Pricing


About This Item

Linear Formula:
(HO)2C6H3CH2CH(NH2)CO2H
CAS Number:
Molecular Weight:
197.19
Beilstein:
2215169
EC Number:
MDL number:
UNSPSC Code:
41116107
PubChem Substance ID:
NACRES:
NA.24

grade

certified reference material
pharmaceutical secondary standard

Quality Level

Agency

traceable to BP 213
traceable to Ph. Eur. L0400000
traceable to USP 1361009

API family

levodopa

CofA

current certificate can be downloaded

technique(s)

HPLC: suitable
gas chromatography (GC): suitable

mp

276-278 °C (lit.)

application(s)

pharmaceutical (small molecule)

format

neat

storage temp.

2-8°C

SMILES string

N[C@@H](Cc1ccc(O)c(O)c1)C(O)=O

InChI

1S/C9H11NO4/c10-6(9(13)14)3-5-1-2-7(11)8(12)4-5/h1-2,4,6,11-12H,3,10H2,(H,13,14)/t6-/m0/s1

InChI key

WTDRDQBEARUVNC-LURJTMIESA-N

Gene Information

human ... DRD3(1814)

Looking for similar products? Visit Product Comparison Guide

General description

Pharmaceutical secondary standards for application in quality control, provide pharma laboratories and manufacturers with a convenient and cost-effective alternative to the preparation of in-house working standards. Levodopa is a metabolic precursor of the neurotransmitter dopamine and is widely used in the treatment of Parkinson′s disease.

Application

Levodopa may be used as a pharmaceutical reference standard for the quantification of the analyte in pharmaceutical formulations using flow injection spectrophotometric method and 1H nuclear magnetic resonance spectroscopy.
These Secondary Standards are qualified as Certified Reference Materials. These are suitable for use in several analytical applications including but not limited to pharma release testing, pharma method development for qualitative and quantitative analyses, food and beverage quality control testing, and other calibration requirements.

Analysis Note

These secondary standards offer multi-traceability to the USP, EP (PhEur) and BP primary standards, where they are available.

Other Notes

This Certified Reference Material (CRM) is produced and certified in accordance with ISO 17034 and ISO/IEC 17025. All information regarding the use of this CRM can be found on the certificate of analysis.

Footnote

To see an example of a Certificate of Analysis for this material enter LRAC2957 in the slot below. This is an example certificate only and may not be the lot that you receive.

Pictograms

Exclamation mark

Signal Word

Warning

Hazard Statements

Hazard Classifications

Acute Tox. 4 Oral - Eye Irrit. 2 - Skin Irrit. 2 - STOT SE 3

Target Organs

Respiratory system

Storage Class Code

11 - Combustible Solids

WGK

WGK 3


Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number

Don't see the Right Version?

If you require a particular version, you can look up a specific certificate by the Lot or Batch number.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Parkinson's Disease and Related Disorders, 506(1), 97-104 (2006)
L H Marcolino-Júnior et al.
Journal of pharmaceutical and biomedical analysis, 25(3-4), 393-398 (2001-05-30)
A flow injection spectrophotometric procedure was developed for determining levodopa in tablets. The determination of this drug was carried out by reacting it with lead(IV) dioxide immobilized in polyester resin packed in a solid-phase reactor and the dopachrome yielded was
Handbook of Parkinson's Disease
Parkinson's Disease and Related Disorders, 506(4), 97-104 (2007)
1H nuclear magnetic resonance spectroscopy analysis for simultaneous determination of levodopa, carbidopa and methyldopa in human serum and pharmaceutical formulations
Talebpour Z, et al.
Analytica Chimica Acta, 506(1), 97-104 (2004)
Roshan Cools
Neuroscience and biobehavioral reviews, 30(1), 1-23 (2005-06-07)
It is well recognised that patients with Parkinson's disease exhibit cognitive deficits, even in the earliest disease stages. Whereas, L-DOPA therapy in early Parkinson's disease is accepted to improve the motor symptoms, the effects on cognitive performance are more complex:

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service